Overview

• A 751-participant trial revealed that tirzepatide (Zepbound) led to an average 20% body weight reduction, compared to 14% with semaglutide (Wegovy).
• Tirzepatide targets two hormones (GLP-1 and GIP), while semaglutide focuses solely on GLP-1, contributing to the efficacy difference.
• Both medications showed similar safety profiles, with mild to moderate gastrointestinal side effects reported by over 75% of participants.
• Observational research suggests GLP-1 receptor agonists may nearly halve the risk of obesity-linked cancers, though further studies are needed.
• UK regulators have tightened online prescribing rules for weight-loss drugs, requiring verified BMI assessments to combat misuse.